Liver Sarcoidosis with Unique MRI Images Using Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid

Nozomu Wada\textsuperscript{a, b,*}, Kazuhiro Nouso\textsuperscript{b}, Kazuya Kariyama\textsuperscript{a}, Akiko Wakuta\textsuperscript{a}, Masayuki Kishida\textsuperscript{a}, Mamoru Nishimura\textsuperscript{a}, and Toshihiro Higashi\textsuperscript{a}

\textsuperscript{a}Liver Disease Center, Okayama Citizen's Hospital, Okayama 700-0833, Japan, and 
\textsuperscript{b}Department of Gastroenterology, Okayama University Hospital, Okayama 700-8558, Japan

Sarcoidosis is a systemic disease characterized by the formation of non-caseating granulomas in multiple organs. In the diagnosis of sarcoidosis, imaging modalities such as ultrasonography, computed tomography (CT) and magnetic resonance imaging (MRI) are useful; however, there are few reports of MRI imaging using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB) MRI. A 46-year-old Japanese female with suspected pulmonary sarcoidosis was admitted to our hospital because low-density mottles in the liver were observed incidentally by chest CT. The low-density mottles were not enhanced at the arterial phase or portal phase by abdominal CT and MRI, and decreased uptake was observed in the hepatobiliary phase of Gd-EOB MRI. No hematological disorder was observed except for a slight increase of biliary enzymes. The lesion was diagnosed as liver sarcoidosis by the liver biopsy. Since the patient refused steroid therapy, we prescribed ursodeoxycholic acid (UDCA) 600 mg/day. The serum levels of biliary enzymes were normalized and the abdominal CT findings gradually improved after the initiation of UDCA medication. Gd-EOB MRI showed unique hypointense areas in the liver at the hepatobiliary phase, which might be useful in the diagnosis of liver sarcoidosis.

Key words: liver sarcoidosis, ursodeoxycholic acid (UDCA), gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB)
ursodeoxycholic acid (UDCA) resulted in improved blood test and imaging results.

Case Presentation

A patient was a 46-year-old Japanese female. Her medical history and family history revealed no remarkable information. In June 2006, she underwent an examination by thoracic radiography, which detected granular shadows in her thorax; she was admitted to our hospital for further examination. A chest X-ray suggested sarcoidosis, and a bronchoscopy was planned. However, the examination was terminated because of suspected xilocaine shock. No significant findings were observed by fundoscopy, echocardiography, and abdominal CT. We then decided to monitor the patient using periodic thoracic radiography and CT examinations at an outpatient clinic.

No subjective symptoms were found. However, in June 2010 an intrahepatic patchy pattern shadow emerged during a thoracic CT examination, and she was therefore admitted again to our hospital for further examination. In the blood test at the time of admission, her alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (γ-GTP) levels were 410 IU/L and 62 IU/L, respectively, which suggested a mild increase in hepatobiliary enzymes. However, her transaminase level was normal, and her AST and ALT levels were 28 IU/L and 19 IU/L, respectively. The angiotensin-converting enzyme (ACE) level was elevated to 35.3 IU/L. The hepatic tumor marker level was also normal; alpha-fetoprotein (AFP) was 3.3 ng/mL.

In a thoracic radiogram, a nodular shadow was observed in the middle zone of the right lung. No undisputable hilar lymph node enlargement was observed. In abdominal ultrasonography, a low echoic area was observed in the hepatic border which corresponded to the map-like low-density area observed during the CT examination. An intrahepatic diffuse map-like low-density area was also detected, but no early- or late-contrast effects were observed in abdominal dynamic CT examination (Fig. 1). In addition, the low-density area detected by CT appeared slightly hypointense on T1-weighted imaging, and slightly hyperintense on T2-weighted imaging in abdominal Gd-EOB MRI (Fig. 2).

The intensity of the liver was lower than that of the spleen in T2-weighted imaging. Similar to the CT results, MRI did not show any contrast effects. In addition, hepatobiliary-phase contrast MRI showed

![Fig. 1 Dynamic CT: The low-density mottles in the liver were observed at the precontrast phase (A), and were not enhanced at the arterial phase (B), portal phase (C) or delayed phase (D).](image-url)
**Fig. 2** Gd-EOB MRI: The low intensity mottles were observed on a T1-weighted image (A), and the high-intensity mottles were observed on a T2-weighted image (B). The mottles were not enhanced at the arterial phase (C) or portal phase (D). Decreased uptake was observed in the hepatobiliary phase (E).

**Fig. 3** Histological findings of the liver needle biopsy (hematoxylin and eosin staining). From the portal region to the liver parenchyma, multiplication of the epithelioid cells containing a multinuclear giant cell was observed.

hypointense lesions. The hypointense area on the hepatobiliary phase in Gd-EOB MRI was slightly larger than the low-density area in dynamic CT.

A liver biopsy was performed in June 2010 to establish a definitive diagnosis. In the pathology investigation, the lobular structure of the liver was
intact, but multinucleated giant cells were detected in
the portal area–peripheral liver parenchyma; multipli-
cation of epithelioid cells was observed (Fig. 3). We
made the diagnosis of liver sarcoidosis with the
pathology findings. Subjective symptoms were not
found; however, pathological changes in the liver and
abnormal levels for biliary enzymes were observed,
and thus steroid treatment was recommended. The
patient expressed a strong preference for taking oral
medications, and thus, oral UDCA 600 mg/day was
initiated.

After the introduction of UDCA, a gradual
improvement was observed in the patient’s blood tests
(Fig. 4). Although an intrahepatic low-density area
was constantly observed during abdominal CT imaging,
the patient continued to show improvement. After 1
year and 7 months of treatment with UDCA, the
patient has not experienced any general health prob-
lems and has been given a good prognosis.

Discussion

Liver sarcoidosis accounts for approx. 20–30% of
all sarcoidosis cases. In Japan, approx. 40–60% of
sarcoidosis cases are detected during autopsy, and
the cases commonly involve the lungs, lymph nodes, and
heart [2]. Most sarcoidosis cases, including our
patient, are asymptomatic, anorexia, general malaise,
and fever are also infrequently reported. Rare sarco-
dosis cases may be associated with portal hyperten-
sion, jaundice, and liver cirrhosis because of vascular
pressure attributable to a granuloma [3, 4].

Imaging findings for liver sarcoidosis generally
involve multiple nodules; however, a few cases,
including our patient, have shown diffuse map-like
lesions. The fusion of nodules has also been reported
in some cases, in which multiple nodular lesions com-
bine into a larger map-like lesion. Hypoechoic nodules
detected during abdominal ultrasonography have also
been reported, although some cases show internal
coarse echo and hyperechoic nodules [5]. Low-
density areas may sometimes be observed in the
affected area during CT imaging without contrast
effect, making it difficult to differentiate between
metastatic liver cancer and liver abscesses [4, 6]. No
patterns in T1- and T2-weighted MRI imaging have
been established for liver sarcoidosis. However,
suppermagnetic iron oxide particle (SPIO) contrast
reduces the intake of the lesion, which results in a
hyperintense image that may be useful for diagnosis.

In our patient, CT imaging demonstrated a low-
density area, whereas in her MRI examination,
T2-weighted images showed hyperintense lesions and
T1-weighted imaging showed hypointense lesions.
These findings suggested an increase in cell density,
which reflects an increase in the amount of water. The
decreased intensity of the liver on T2-weighted images
was emphasized by comparing the intensity of the spleen.
A difference in intensity between the liver area and spleen
was also reported by Chundru et al. [7], and this finding
might be ubiquitous in liver sarco-
dosis. In our patient, the intensity of liver sarco-
dosis was similarly lower than that of the spleen on
T2-weighted images. We speculate that the sarcoid
nodules destroyed normal liver tissue, and thus the
blood flow to the liver was reduced. The reduction in
blood flow in the sarcoid nodules might thus have
affected the contrast of the sarcoid lesion and the
A reduction in blood flow in the lesion has also inhibited the contrast effect of imaging. A reduction in the intake of the contrast dye, which is attributable to the destruction of normal liver tissue, resulted in the generation of hypointensity on the hepatobiliary phase. In our patient’s case, we observed that the hypointense area on the hepatobiliary phase in Gd-EOB MRI was slightly larger than the low-density area in dynamic CT, suggesting that the liver cell function was deteriorated without the reduction of blood flow at the boundary of the lesion. There are few reports showing the intake of Gd-EOB by hepatocytes, which might shed light on the liver function of sarcoidosis.

In the absence of imaging results or in cases of undetectable impairment of liver function, approx. 80% of liver sarcoidosis cases are diagnosed using laparoscopic liver biopsy [8]. A clinicopathological report of 100 cases of liver sarcoidosis [9] included findings such as cholestatic disorder, a mix of cholestatic disorder and hepatocyte damage, and hepatitis; all cases showed varying degrees of non-caseating granuloma, as well as multinucleated giant cells and asteroid bodies.

In the present case, UDCA was effective. The mechanism of action of UDCA involves immunoregulation. It was reported that UDCA modulates the action of nuclear glucocorticoid receptors [10–12], thus suggesting that its effect may be attributable to its steroid-like action.

**Conclusion**

Our patient’s case involved sarcoidosis of the liver with unique Gd-EOB MRI findings and successful treatment with oral UDCA.

**References**